Evidence map›Paper›PMID 41612081›Full record

SynthesisInternational journal of clinical oncology2026

Comparison of nedaplatin and cisplatin in concurrent chemoradiotherapy for cervical cancer: a systematic review and meta-analysis.

Maki Umemiya, Kazuhiro Kou, Yoshihide Inayama, Jun Kamei, Ken Yamaguchi, Yoshie Yamada, Takahiro Itaya, Yosuke Yamamoto, Masaki Mandai, Yusuke Ogawa

Abstract readSystematic ReviewMeta-AnalysisComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Maki UmemiyaDepartment of Gynecology and Obstetrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0002-5097-3543
Kazuhiro KouDepartment of Gynecology and Obstetrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0009-0002-5403-7717
Yoshihide InayamaDepartment of Gynecology and Obstetrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0003-2040-5913
Jun KameiDepartment of Healthcare Epidemiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0001-9150-1529
Ken YamaguchiDepartment of Obstetrics and Gynecology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.ORCID http://orcid.org/0000-0002-7669-1405
Yoshie YamadaDepartment of Healthcare Epidemiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0002-0424-3750
Takahiro ItayaDepartment of Healthcare Epidemiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0002-0560-8686
Yosuke YamamotoDepartment of Healthcare Epidemiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0003-1104-2612
Masaki MandaiDepartment of Gynecology and Obstetrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0003-4428-8029
Yusuke OgawaDepartment of Healthcare Epidemiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. ogawa.yusuke.2u@kyoto-u.ac.jp.ORCID http://orcid.org/0000-0001-9256-5102

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCisplatin-based concurrent chemoradiotherapy (CCRT) is the standard treatment for locally advanced cervical cancer; however, its nephrotoxicity and gastrointestinal toxicity often limit treatment eligibility and completion. Nedaplatin, a cisplatin analogue with reduced renal and gastrointestinal toxicity, has been increasingly used in East Asia, but its comparative efficacy and safety in cervical cancer have not been comprehensively evaluated.

methodsWe systematically searched MEDLINE, Embase, CENTRAL, CNKI, Ichushi Web, ICTRP, and ClinicalTrials.gov for randomized controlled trials comparing nedaplatin versus cisplatin-based CCRT. The primary efficacy outcome was all-cause mortality at 3 years, and the primary safety outcome was renal toxicity. Secondary outcomes included mortality at 1 and 5 years, progression or mortality, hematologic and gastrointestinal toxicities, liver dysfunction, and quality of life. Random-effects meta-analyses were performed using risk ratios.

resultsSeventeen trials met the eligibility criteria. All-cause mortality at 3 years did not differ significantly between the groups (RR 0.88; 95% CI 0.51-1.51; I

conclusionNedaplatin showed fewer adverse effects and comparable or improved short-term outcomes compared with cisplatin. These findings support nedaplatin as a potential alternative for patients who are cisplatin-intolerant or frail. Confirmation in large, high-quality trials with long-term follow-up and patient-reported outcomes is warranted.

Indexed as

Antineoplastic AgentsChemoradiotherapyCisplatinOrganoplatinum CompoundsUterine Cervical NeoplasmsFemaleHumansQuality of LifeRandomized Controlled Trials as TopicAntineoplastic AgentsCisplatinnedaplatinOrganoplatinum CompoundsCervical cancerChemoradiotherapyCisplatinMeta-analysisNedaplatin

Identifiers

PMID41612081
PMCPMC12932270

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.